30 related articles for article (PubMed ID: 17087656)
1. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.
Shadfan BH; Simmons AR; Simmons GW; Ho A; Wong J; Lu KH; Bast RC; McDevitt JT
Cancer Prev Res (Phila); 2015 Jan; 8(1):37-48. PubMed ID: 25388014
[TBL] [Abstract][Full Text] [Related]
2. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.
Holdenrieder S; Molina R; Gion M; Gressner A; Troalen F; Auge JM; Zancan M; Wycislo M; Stieber P
Clin Chem Lab Med; 2008; 46(5):588-99. PubMed ID: 18598201
[TBL] [Abstract][Full Text] [Related]
3. Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125.
Bayoumy S; Hyytiä H; Leivo J; Talha SM; Huhtinen K; Poutanen M; Hynninen J; Perheentupa A; Lamminmäki U; Gidwani K; Pettersson K
Commun Biol; 2020 Aug; 3(1):460. PubMed ID: 32826955
[TBL] [Abstract][Full Text] [Related]
4. Advances in the early detection of ovarian cancer: How to hear the whispers early.
Cesario S
Nurs Womens Health; 2010 Jun; 14(3):222-34. PubMed ID: 20579298
[No Abstract] [Full Text] [Related]
5. Rapid, label-free, electrical whole blood bioassay based on nanobiosensor systems.
Chang HK; Ishikawa FN; Zhang R; Datar R; Cote RJ; Thompson ME; Zhou C
ACS Nano; 2011 Dec; 5(12):9883-91. PubMed ID: 22066492
[TBL] [Abstract][Full Text] [Related]
6. A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not.
Dorizzi RM; Meneghelli S; Rocca M; Ferrari A
Clin Chem Lab Med; 2006; 44(11):1386-7; author reply 1388. PubMed ID: 17087656
[No Abstract] [Full Text] [Related]
7. Limitations to the use of the CA-125 antigen level in ovarian cancer.
Markman M
Curr Oncol Rep; 2003 Jul; 5(4):263-4. PubMed ID: 12781066
[No Abstract] [Full Text] [Related]
8. The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.
Selman AE; Copeland LJ
Curr Oncol Rep; 1999 Sep; 1(1):71-6. PubMed ID: 11122801
[TBL] [Abstract][Full Text] [Related]
9. CA 125 in benign gynecological conditions.
Meden H; Fattahi-Meibodi A
Int J Biol Markers; 1998; 13(4):231-7. PubMed ID: 10228907
[TBL] [Abstract][Full Text] [Related]
10. Clinical practice. Screening for ovarian cancer.
Clarke-Pearson DL
N Engl J Med; 2009 Jul; 361(2):170-7. PubMed ID: 19587342
[No Abstract] [Full Text] [Related]
11. [Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology].
Sehouli J; Stengel D; Hindenburg J; Camara O; Porzsolt F; Lichtenegger W;
Zentralbl Gynakol; 2001 Mar; 123(3):127-31. PubMed ID: 11340951
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour markers in ovarian tumours.
von Schlippe M; Rustin GJ
Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]